These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 3489774)

  • 1. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
    Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
    J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced lytic susceptibility of Ha-ras transformants after oncogene induction is specific to activated NK cells.
    Johnson PW; Trimble WS; Hozumi N; Roder JC
    J Immunol; 1987 Jun; 138(11):3996-4003. PubMed ID: 3495578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
    Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
    Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT; Eisenthal A; Rosenberg SA
    J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL; Herberman RB; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Ha-ras-I oncogene-induced differentiation and natural killer cell resistance in a human colorectal carcinoma cell line.
    Bagli DJ; D'Emilia JC; Summerhayes IC; Steele GD; Barlozzari T
    Cancer Res; 1990 Apr; 50(8):2518-23. PubMed ID: 2180571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
    Dannemann BR; Morris VA; Araujo FG; Remington JS
    J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
    Kaufmann Y; Levanon M; Davidsohn J; Ramot B
    J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.
    Donskov F; Basse PH; Hokland M
    Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and characterization of purified adherent lymphokine-activated killer cells in mice.
    Gunji Y; Vujanovic NL; Hiserodt JC; Herberman RB; Gorelik E
    J Immunol; 1989 Mar; 142(5):1748-54. PubMed ID: 2783950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
    Lynch DH; Miller RE
    J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
    de Fries RU; Golub SH
    J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.